Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.

@article{Ferri2011TreatmentWR,
  title={Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.},
  author={Clodoveo Ferri and Patrice Cacoub and Cesare Mazzaro and Dario Roccatello and Patrizia Scaini and Marco Sebastiani and Antonio Gaetano Tavoni and Anna Linda Zignego and Salvatore de Vita},
  journal={Autoimmunity reviews},
  year={2011},
  volume={11 1},
  pages={48-55}
}
OBJECTIVE Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by multiple organ involvement due to the vascular deposition of immune-complexes, mainly the cryoglobulins. B-lymphocyte expansion represents the underlying pathological alteration frequently triggered by hepatitis C virus (HCV) infection. The treatment of MCs syndrome is generally based on antiviral drugs and/or immunosuppressors, among which rituximab, an anti-CD20 monoclonal antibody, has been usefully… CONTINUE READING
46 Citations
61 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 61 references

A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome

  • S De Vita, L Quartuccio, M Isola, P Masolini, S Sacco, G De Marchi
  • Arthritis Rheum 2011;62:S924
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…